chronic hepatitis C
Conditions
Interventions
1)DFPP therapy Transplant recipients receive DFPP therapy 3 days before and during living donor liver transplantation (for 4 hours and 10 hours, respectively) to remove hepatitis C virus. 2)Adoptive
Sponsors
Hiroshima University Hospital, Department of surgery
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The subjects must be satisfactory the following conditions. 1)Patients must consent to adoptive immunotherapy with liver allograft derived lymphocytes 2)Patients must have HCV liver cirrhosis for which liver transplantation is best indicated. 3)Patients must be equal to or more than 20 years old. 4)Written informed consent must be obtained from patients.
Exclusion criteria
Exclusion criteria: The following patients must be excluded. 1)Recipients with fluminant hepatitis 2)ABO blood type incompatible recipients 3)Recipients of re-transplantation 4)Recipients of deceased donor liver transplantation 5)Patients with the past history of severe shock reactions to any therapy using extracorporeal circulation. 6)Patients who have un-controlable heart disease 7)Patients who are participated in other clinical study within 3 months. 8)Patients who are during pregnancy, lactation expectant, and desiring future fertility. 9)Patients who are judged inappropriate for the clinical trial by doctors. 10)Patients with the past history of severe allergic reactions to nafamostat mesilate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of antivirus activity (recurrence rate of HCV RNA) of DFPP and adoptive immunotherapy combination therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Evaluation of virus reduction effect by DFPP and adoptive immunotherapy combination therapy 2.Adverse effects of DFPP and adoptive immunotherapy combination therapy | — |
Countries
Japan
Contacts
Public ContactTakashi Onoe
Hiroshima University Hiroshima University Hospital, Department of surgery
Outcome results
None listed